Search Results - "Ranjbar, Sheyda"

A holistic analysis of the intrinsic and delivery-mediated toxicity of siRNA therapeutics by Ranjbar, Sheyda, Zhong, Xiao-bo, Manautou, José, Lu, Xiuling

“…[Display omitted] Small interfering RNAs (siRNAs) are among the most promising therapeutic platforms in many life-threatening diseases. Owing to the…”
Get full text

The quest for a better fight: How can nanomaterials address the current therapeutic and diagnostic obstacles in the fight against COVID-19? by Ranjbar, Sheyda, Fatahi, Yousef, Atyabi, Fatemeh

“…The inexorable coronavirus disease 2019 (COVID-19) pandemic with around 226 million people diagnosed and approximately 4.6 million deaths, is still moving…”
Get full text

Emerging Roles of Probiotics in Prevention and Treatment of Breast Cancer: A Comprehensive Review of Their Therapeutic Potential by Ranjbar, Sheyda, Seyednejad, Seyed Afshin, Azimi, Haniye, Rezaeizadeh, Hossein, Rahimi, Roja

“…Breast cancer is the most common cancer among women. Need for novel preventive and curative approaches with more safety than the present one seems inevitable…”
Get full text

Targeting non-apoptotic cell death in cancer treatment by nanomaterials: Recent advances and future outlook by Sepand, Mohammad Reza, Ranjbar, Sheyda, Kempson, Ivan M, Akbariani, Mostafa, Muganda, Willis Collins Akeyo, Müller, Mareike, Ghahremani, Mohammad Hossein, Raoufi, Mohammad

“…Many tumors develop resistance to most of the apoptosis-based cancer therapies. In this sense targeting non-apoptotic forms of cell death including…”
Get full text

Reduced polydopamine coated graphene for delivery of Hset1 antisense as A photothermal and gene therapy of breast cancer by Babavalian, Anahita, Tekie, Farnaz Sadat Mirzazadeh, Ayazi, Hossein, Ranjbar, Sheyda, Varshochian, Reyhaneh, Rad-Malelkshahi, Mazda, Akhavan, Omid, Dinarvand, Rassoul

“…Breast cancer is the most prevalent type of cancer in women; hence, many researches have been focused on developing effective treatment protocols. In this…”
Get full text

How can we develop better antispasmodics for irritable bowel syndrome? by Ranjbar, Sheyda, Seyednejad, Seyed Afshin, Nikfar, Shekoufeh, Rahimi, Roja, Abdollahi, Mohammad

“…Irritable bowel syndrome (IBS) is a prevalent gastrointestinal (GI) disease. Antispasmodics are a heterogeneous group of drugs that tackle IBS-associated…”
Get more information